Clinical implications of the dual blockade of the PD-1/PD-L1 and vascular endothelial growth factor axes in the treatment of hepatocellular carcinoma.
Clinical implications of the dual blockade of the PD-1/PD-L1 and vascular endothelial growth factor axes in the treatment of hepatocellular carcinoma.
复制标题
DOI：
10.21037/hbsn.2019.10.18
复制
发表时间：
2020-10
影响因子：
8
通讯作者：
N. Nishida
中科院分区：
文献类型：
--
作者：
N. Nishida
目前，肝癌是全球癌症死亡的第四大常见原因。绝大多数肝癌是肝细胞癌（HCC），在慢性肝病的背景下发展，包括慢性肝炎B、慢性肝炎C和非酒精性脂肪性肝炎（1）。尽管最近在HCC的治疗方面取得了进展，但它在很大程度上仍然是难治性的，即使在治疗干预后复发率也很高（2）。许多药物，包括酪氨酸激酶抑制剂（TKI）、阻断血管内皮生长因子（VEGF）/VEGF受体（VEGFR）轴的抗体和免疫检查点抑制剂，现在可用于治疗晚期HCC（3）。然而，它们的抗肿瘤反应仍然不令人满意。
Currently, liver cancer is the fourth most common cause of cancer mortality worldwide. The overwhelming majority of liver cancers are hepatocellular carcinomas (HCC), developing on the background of chronic liver diseases, including chronic hepatitis B, chronic hepatitis C, and non-alcoholic steatohepatitis (1). Despite the recent progress in the treatment of HCC, it remains largely refractory, with a high recurrence rate even after therapeutic intervention (2). Numerous agents, including tyrosine-kinase inhibitors (TKIs), antibodies blocking the vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) axis, and immune checkpoint inhibitors, are now available for the treatment of advanced stage HCC (3). However, their antitumor responses are still unsatisfactory.